Healthcare / Medical Instruments & SuppliesNasdaqGM
$3.02
+0.04 (+1.34%)
FCF base 3Y
n/d
n/d CAGR · yield n/d
FCF base 5Y
n/d
n/d base · n/d expected
Precio de entrada
n/d
MOS 33% · confianza 24%
FCF escenarios
weak_data · normalized FCF $-55.7M · quality 70.7/100
Ranking barato/determinista: CAGR esperado 5Y + downside bear + calidad del modelo + balance + capital allocation + data gate. No entra en buy-candidate si la data es débil o el CAGR 5Y no compensa.
SA Score
17/100
F
Piotroski
2/9
balance/quality
Valuation
50/100
+0.0% upside
5Y CAGR
+0.0%
50/100
Data QA
16/100
SEC 0%
Sin guardar todavía.
Market Cap
$135M
P/E
N/A
•EV/EBITDA
N/A
•ROE
-183.4%
↓Gross Margin
63.1%
↑Debt/Equity
0.82
↑TradingView lightweight chart
Absolute Values (Left Axis)
Ratios / Percentages (Right Axis)
Financial statement dashboard
2022–2025 · 3 años de histórico normalizado
Revenue CAGR
+48.1%
FCF CAGR
—
FCF margin
-726.0%
FCF / Net income
0.81x
Latest source
Provider fallback
Margin decomposition
Último año: revenue $10.0M · net income $-90.1M · FCF $-72.7M
Gross margin
Operating margin
Net margin
FCF margin
| Metric | TTM | 2025 | 2024 | 2023 | 2022 |
|---|---|---|---|---|---|
| Income Statement | |||||
| Revenue | $10.0M | $10.0M | $4.5M | $4.3M | $3.1M |
| Net Income | $-90.1M | $-90.1M | $-59.2M | $-43.2M | $-31.2M |
| EBITDA | $-82.9M | $-82.9M | $-52.8M | $-42.1M | $-27.9M |
| EPS | -2.36 | -2.36 | -1.81 | -1.54 | -1.21 |
| Gross Margin | 63.1% | 63.1% | 65.7% | 61.9% | 62.7% |
| Operating Margin | -827.8% | -827.8% | -1300.8% | -1037.3% | -1053.8% |
| Net Margin | -899.1% | -899.1% | -1310.2% | -993.8% | -1012.5% |
| Balance Sheet | |||||
| Debt/Equity | 0.82 | 0.82 | 0.20 | 0.13 | 0.10 |
| Current Ratio | 0.99 | 0.99 | — | — | — |
| Cash Flow | |||||
| Free Cash Flow | $-72.7M | $-72.7M | $-55.3M | $-55.7M | $-45.1M |
| Returns | |||||
| ROE | -183.4% | -183.4% | -52.3% | -44.1% | -26.0% |
| Valuation | |||||
| P/B | 2.34 | 2.34 | 2.65 | 1.33 | 1.13 |
| Growth & Yield | |||||
| Revenue Growth | 121.6% | 121.6% | 4.0% | 41.0% | — |
| EPS Growth | -30.7% | -30.7% | -17.1% | -27.8% | — |
Revenue, Net Income & Free Cash Flow ($B)
Margins (%)
Returns (%)
Leverage & Liquidity
Qué te dice: cuánto EPS CAGR está descontando el precio si sales al múltiplo terminal indicado. Si el growth observado queda por debajo, el mercado está pidiendo una ejecución muy fina.
Total return
-60.5%
Start / end P/E
n/dx → n/dx
EPS bridge
-1.81 → -2.36
Residual
-60.5%
EPS/multiple decomposition requires positive EPS at both endpoints; residual absorbs price move not explained by dividends.
Simple additive decomposition: total return = EPS growth contribution + P/E multiple contribution + dividend contribution + explicit residual. The residual captures cross-terms, buybacks/share-count effects, FX, special dividends, data noise and methodology mismatch so the bridge always reconciles.